Pfizer has spent billions of dollars on acquisitions in the past few decades. Its biggest deals include Warner-Lambert, ...

After a years-long revenue drought, there's a light at the end of the tunnel.

Pfizer Inc. (NYSE:PFE) is one of the best inexpensive stocks to buy now. On January 20, Novavax announced a non-exclusive licensing agreement with Pfizer, granting the pharmaceutical giant access to ...

But while the rankings held steady, the operating environment has changed quickly to reinforce the value of being in good ...

Pfizer is paying $30 million to use Novavax’s adjuvant technology to improve the efficacy of two of the Big Pharma’s vaccine ...

Last week, US pharma giant Pfizer chairman and chief executive Albert Bourla presented at the JP Morgan Healthcare Conference ...

Facing the loss of exclusivity on key products, Pfizer has pulled forward its lead obesity asset into Phase III and targeted a 2028 launch. CEO Albert Bourla explained the pharma's strategy at J.P.

The deal on drug prices between the US Administration and Pfizer will leave the margins of innovative pharma companies intact. Yet, benefits to consumers will be modest. Furthermore, prices for ...

Johnson & Johnson JNJ and Pfizer PFE rank among the world’s largest pharmaceutical companies, each with broad and diversified healthcare portfolios. J&J operates primarily through its pharmaceuticals ...

Approved eight months ago for a certain class of patients with both hemophilia A or B, Pfizer’s Hympavzi has now shown its effectiveness in another group of patients with the bleeding disorder. That's ...

The healthcare giant has had trouble winning over investors in the past year despite an incredibly low valuation.

Pfizer Inc. (PFE) shares are trading higher on Tuesday, as the stock benefits from a price target increase at Cantor ...